QRG Capital Management Inc. lifted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 16.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 329,644 shares of the company's stock after buying an additional 47,490 shares during the period. QRG Capital Management Inc.'s holdings in Takeda Pharmaceutical were worth $4,364,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the business. Lake Street Advisors Group LLC bought a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $139,000. Bank of New York Mellon Corp boosted its holdings in Takeda Pharmaceutical by 17.2% in the fourth quarter. Bank of New York Mellon Corp now owns 104,892 shares of the company's stock worth $1,389,000 after purchasing an additional 15,388 shares during the last quarter. Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter worth approximately $61,000. Ieq Capital LLC raised its stake in Takeda Pharmaceutical by 86.9% during the 4th quarter. Ieq Capital LLC now owns 21,241 shares of the company's stock valued at $281,000 after buying an additional 9,874 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after buying an additional 4,260 shares during the period. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Stock Performance
Shares of TAK traded up $0.05 during trading hours on Tuesday, hitting $14.89. The stock had a trading volume of 1,521,240 shares, compared to its average volume of 1,842,975. The firm has a market capitalization of $47.36 billion, a PE ratio of 37.21, a PEG ratio of 0.24 and a beta of 0.51. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The stock has a fifty day moving average price of $13.44 and a 200 day moving average price of $13.89.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
